In conclusion, this study demonstrated that LukS-PV increased the acetylation level of α-tubulin via HDAC6, thereby inhibiting the migration of HCC cells, indicating that LukS-PV may have potential as a promising candidate for the treatment of HCC. Here, HDAC6 is linked to hepatocellular carcinoma.